Antihypertensives - Two Years to Shape the Market?

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor expects the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to be savvy regarding marketing and pricing structures for their products, as only the most cunning and aggressive companies look set to survive.


Scope

  • Event-driven sales forecasts, for the period 2005-14, for the US, Japan, France, Germany, Italy, Spain and the UK, along with a global overview
  • Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs
  • Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches
  • Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform


    • Report Highlights
    The ARBs are now the most prescribed class of antihypertensives, as aggressive marketing and premium-pricing enables manufacturers to deliver strong growth in a highly genericized market. Post-2009, however, the value of the ARB class is set to flatten on the back of generic erosion and indication expansion for the ARBs as a class.

    In order for companies to achieve and maintain growth in this sector, companies need to be savvy regarding the impact of healthcare reform across the globe, particularly in Europe, with marketers who are charged with selling drugs across the EU needing to challenge the attitude that Europe is one, uniform, market like the US and Japan.

    Novartis' SPP100 (aliskiren) looks set to become the first innovative treatment for hypertension in over a decade. However, due to concerns regarding premium-pricing and similar efficacy compared to the ARBs, market penetration is expected to be slow in the short-term until strong cardiovascular outcome data for the class becomes available.


    Reasons to Purchase

  • Access independent, event-driven forecasts for key antihypertensive products and classes across the seven major markets
  • Assess the potential impact of clinical trial results, EU healthcare reform and new product launches on the antihypertensive market
  • Gain insight into the antihypertensive market via up-to-date thought-leader opinions and gold-standard IMS Health sales data

    • Table of Contents

    Other users found this report page using the following search terms: hypertension antihypertensive blood pressure ace arb market antihypertensive arb antihypertensives drugs patent sales hypertension expiry drug

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.